Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1054

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 8
Chunk 1054
---
,981,155

			Total liabilities and shareholders' equity

			$
			13,530,518

			$
			3,813,982

The accompanying notes are an integral part of these consolidated financial statements.

F-4

EDESA BIOTECH, INC.

Consolidated Statements of Operations and Comprehensive Loss

			Fiscal Year End 

			September 30, 2025

			September 30, 2024

			Expenses:

			Research and development

			$
			3,668,738

			$
			2,881,967

			General and administrative

			4,242,828

			4,132,777

			Loss from operations

			(7,911,566
			)

			(7,014,744
			)

			Other income :

			Reimbursement grant income

			783,894

			698,277

			Interest income

			2,558

			153,498

			Misc other income

			-

			14,766

			Foreign exchange (loss)

			(59,609
			)

			(21,042
			)

			726,843

			845,499

			Loss before income taxes

			(7,184,723
			)

			(6,169,245
			)

			Income tax expense

			800

			800

			Net loss

			(7,185,523
			)

			(6,170,045
			)

			Exchange differences on translation

			76,842

			(27,965
			)

			Net comprehensive loss

			$
			(7,108,681
			)
			 
			$
			(6,198,010
			)

			Weighted average number of common shares

			5,676,708

			3,197,423

			Loss per common share - basic and diluted

			$
			(1.27
			)
			 
			$
			(1.93
			)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

EDESA BIOTECH, INC.

Consolidated Statements of Cash Fl